MedTrace Logo

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

NCT04910126 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-06-02

No results posted yet for this study

Summary

To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma

Conditions

  • Soft Tissue Sarcoma
  • Neoplasms, Connective and Soft Tissue
  • Sarcoma Metastatic
  • Sarcoma,Soft Tissue

Interventions

DRUG

Camrelizumab

Camrelizumab 200mg q3w up to 2 years

DRUG

Adriamycin

adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Jing Chen, MD, PhD · Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2023-01-12
Completion
2023-11-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910126 on ClinicalTrials.gov